ASCEND · 101MS326
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of natalizumab in reducing disability progression in patients with secondary progressive multiple sclerosis. EudraCT: 2010-021978-11.
Sponsor: BIOGEN
Phase: III
Area: Neuroimmunology